Anti-SARS-CoV-2 S1 (RBD) Neutralizing Antibody (V3S-0723-XY13) (CAT#: V3S-0723-XY13)

Send Inquiry
  • fig1

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description The product is a highly potent antibody against Omicron Spike S1 with IC₅₀ values of 6 ng/ml. The antibody bound Omicron S with 5- to 40-fold lower affinity compared with their binding to WT Spike. This product has been tested using Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay.
Clonality Monoclonal
Host Species Human
Target Species SARS-CoV-2 (Omicron)
Immunogen CoronaVac (Sinovac) inactivated virus vaccine
Epitope The epitope at the tip of the RBD overlapping largely with the patch targeted by ACE2.

Property

Expression Species HEK293F or CHO cell line
Conjugation Unconjugated
Purity >95%
Endotoxin <1 EU/mg
Form Liquid
Purification Protein A purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics.

Applications

Application ELISA; BLI; Neut
Application Notes This antibody has been tested by ELISA and Neutralization assay. The ELISA was done using antibody started at 25 μg/mL with a serial 1:2 dilution. The neutralization assay against Omicron was done with an IC₅₀ value of 6 ng/mL.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target SARS-CoV-2 S1
Alternative Name Severe acute respiratory syndrome coronavirus 2 Spike S1
Research Area Coronavirus Disease 2019
Related Disease Coronavirus Disease 2019
For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
ISO 9001 Certified - Creative Biolabs Quality Management System.
Online Inquiry